Found: 9
Select item for more details and to access through your institution.
An oral antisense oligonucleotide for PCSK9 inhibition.
- Published in:
- Science Translational Medicine, 2021, v. 13, n. 593, p. 1, doi. 10.1126/scitranslmed.abe9117
- By:
- Publication type:
- Article
Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial.
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 10, p. 2493, doi. 10.1111/cts.13377
- By:
- Publication type:
- Article
Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide.
- Published in:
- British Journal of Clinical Pharmacology, 2024, v. 90, n. 6, p. 1503, doi. 10.1111/bcp.16046
- By:
- Publication type:
- Article
AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 11, p. 4839, doi. 10.1111/bcp.15425
- By:
- Publication type:
- Article
Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator.
- Published in:
- British Journal of Clinical Pharmacology, 2018, v. 84, n. 7, p. 1486, doi. 10.1111/bcp.13562
- By:
- Publication type:
- Article
Comparable pharmacokinetics and pharmacodynamics of melagatran in Japanese and caucasian volunteers after oral administration of the direct thrombin inhibitor ximelagatran.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men.
- Published in:
- 2006
- By:
- Publication type:
- journal article
A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2022, v. 11, n. 12, p. 1569, doi. 10.1002/psp4.12866
- By:
- Publication type:
- Article
Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study.
- Published in:
- CTS: Clinical & Translational Science, 2020, v. 13, n. 2, p. 275, doi. 10.1111/cts.12705
- By:
- Publication type:
- Article